← All trials
NCT01890265
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2013
- Primary completion
- Jun 1, 2017
- Completion date
- Jul 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- FibroGenLead sponsor
- Northwestern UniversityOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- University of LouisvilleOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- University of UtahOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- University of Alabama, BirminghamOverall official - principal investigator
- Avanza ResearchOverall official - principal investigator
- Dartmouth UniversityOverall official - principal investigator
- Life Mount Edgecombe Hospital, South AfricaOverall official - principal investigator
- Into Research, South AfricaOverall official - principal investigator
- Daw Park Repatriation, AustraliaOverall official - principal investigator
- Dunedin Public Hospital, New ZealandOverall official - principal investigator
- Tauranga Hospital, New ZealandOverall official - principal investigator
- Fortis Hospitals, IndiaOverall official - principal investigator
- Midland Healthcare & Research Center, IndiaOverall official - principal investigator
- Sri Bala Medical Centre and Hospital, IndiaOverall official - principal investigator
- Pulmonix LLC, USAOverall official - principal investigator
- Stellenbosch UniversityOverall official - principal investigator
- University of California, DavisOverall official - principal investigator
- Henry Ford Health SystemOverall official - principal investigator
- University of SydneyOverall official - principal investigator
- Legacy Health SystemOverall official - principal investigator
- Vermont Lung CenterOverall official - principal investigator
- Tufts UniversityOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- University of Colorado, DenverOverall official - principal investigator
- Columbia UniversityOverall official - principal investigator
- University of KansasOverall official - principal investigator
- Bharti HospitalOverall official - principal investigator
- University of OtagoOverall official - principal investigator
- Rajiv Gandhi University of Health SciencesOverall official - principal investigator
- Tokuda HospitalOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- Via Christi Regional Medical CenterOverall official - principal investigator
- Waikato HospitalOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.